Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

Glioblastoma Multiforme (GBM) Clinical Trial

Official title:
Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

Status Terminated

Clinical Trial Summary

The objective of the study is to assess the safety and efficacy of treatment with hypothyroxinemia adjunct to conventional therapies in GBM patients.

Clinical Trial Description

Since T4 (thyroxine) is a potent growth factor in numerous cancer types, the interventional approach will be to achieve thyroxine deprivation (hypothyroxinemia).This can be achieved by using a dual approach: T3 and methimazole to provide longer term inhibition of thyroid hormone synthesis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02654041
Study type	Interventional
Source	Musli Thyropeutics Ltd.
Contact
Status	Terminated
Phase	Phase 2
Start date	March 2016
Completion date	June 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04587830` - ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme	Phase 1
Completed	`NCT01109095` - CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM	Phase 1
Active, not recruiting	`NCT04019002` - Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma	Phase 1
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Withdrawn	`NCT01788280` - Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab	Phase 2
Completed	`NCT01238237` - Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA	Phase 1
Completed	`NCT02202993` - TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM	Phase 1